Tag: Hans Schambye
Galecto raises $64m to develop fibrosis and cancer treatments
Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments for fibrosis and cancer. Led by Soleus ... Read More
Galecto Biotech raises €79m to launch idiopathic pulmonary fibrosis trial
Galecto Biotech, a Denmark-based pharma company focused on developing galectin modulators for the treatment of severe diseases such as idiopathic pulmonary fibrosis and cancer, has ... Read More